Aedes aegypti in India
The Indian sub-continent has suffered as much as anywhere from the global rise in the prevalence of mosquito-borne diseases. In India alone, the case numbers are staggering: every year tens of millions of people are estimated to suffer from dengue, just one of the devastating diseases transmitted by the Aedes aegypti mosquito. These diseases are also taking a toll on the Indian economy. Recent published work estimated that including lost productivity, the total financial cost of dengue to India is over US$1 billion per year – and dengue is not the only danger posed by Aedes aegypti: the same mosquito is responsible for recent chikungunya outbreaks in the country, and is also the primary carrier of the Zika virus.
Read more about how our solution works here.
GBIT Contact Details:
R & D Office
Gangabishan Bhikulal Investment & Trading Limited (GBIT)
At: Dawalwadi; Tq: Badnapur
P.O. Box – 76, Jalna – 431 203,
Maharashtra State, India
Ph: 02482 – 262471/262371-75
We are working with our partner Gangabishan Bhikulal Investment and Trading Limited (GBIT), to assess the effectiveness of our Friendly™ mosquitoes in suppressing local strains of this dangerous pest in India.
Our collaboration began in 2011 with laboratory work to evaluate Friendly™ mosquitoes against local strains from Delhi and Aurangabad. In 2017, we began conducting outdoor caged trials with the Friendly™ mosquitoes in Dawalwadi.
After we have analyzed the results from the current trials in netted cages, we plan to proceed to conduct outdoor trials. These trials will only begin following approval by the Indian regulatory bodies and after a period of community engagement.
Patil PB, Gorman KJ, Dasgupta SK, Reddy KVS, Barwale SR, Zehr UB (2018) Self-Limiting OX513A Aedes aegypti demonstrate full susceptibility to currently used insecticidal chemistries as compared to Indian wild-type Aedes aegypti. Psyche, vol. 2018, Article ID 7814643, 7 pages.
OPEN ACCESS: https://doi.org/10.1155/2018/7814643